Pharma Stock Soars to Record Highs After Epilepsy Treatment Results

The company reported positive data for its epilepsy treatment

Deputy Editor
Oct 4, 2021 at 1:32 PM
facebook twitter linkedin

Xenon Pharmaceuticals Inc (NASDAQ:XENE) stock is soaring today, up 90.8% to trade at $29.76 at last glance, after the company met its main goal in a phase 2 study of its epilepsy treatment XEN1101. Today's pop has XENE nabbing a fresh record high, as well as jumping over a slew of key moving averages and recent pressure at the $19 level. Year-over-year, the equity sports a 162.8% lead.
The options pits are bursting with activity. So far, 9,318 calls and 23,000 puts have crossed the tape, with volume pacing for the top percentile of its annual range, and already 10.9 times its usual daily average. The October 25 put is the most popular, followed by the 20 put in the same monthly series, with new positions being opened at both.
Plus, Jefferies raised its price target to $50 from $28, which is made more notable by the fact that analysts are already quite bullish on XENE. In fact, all six in coverage sport a "strong buy" rating on the stock, and the pre-adjustment 12-month consensus price target of $39.63 stands at a 33% premium to current levels. 



Minimize Risk While Maximizing Profits

There is no options strategy like this one, which consistently minimizes risk while maintaining maximum profits. Perfect for traders looking for ways to control risk, reduce losses, and increase the likelihood of success when trading calls and puts. The Schaeffer’s team has over 41 years of options trading success targeting +100% gains on every trade. Rest assured your losses are effectively limited to your initial cost at the time of making your move! Don't waste another second... join us right now before the next trade is released! 



Special Offers from Schaeffer's Trading Partners